What is Oration?
Oration is a technology company focused on revolutionizing prescription management. Its flagship product, OrationRx, is a prescription management application designed to simplify the process of shopping for and purchasing medications. The platform empowers employers, particularly self-insured entities with over 10,000 employees, and their employees to identify the most cost-effective pharmacies and manage prescriptions in real-time. By analyzing drug transactions, OrationRx aims to deliver substantial annual savings, potentially exceeding $1 million for its clients. The company has processed over $2 billion in drug transactions, demonstrating its significant impact on the healthcare cost landscape. Founded in 2012, Oration has attracted investment from a notable roster of venture capital firms and individual investors.
How much funding has Oration raised?
Oration has raised a total of $12.2M across 2 funding rounds:
Angel/Seed
$1M
Series A
$11.2M
Angel/Seed (2014): $1M, investors not publicly disclosed
Series A (2014): $11.2M led by Chicago Ventures, Arsenal Venture Partners, Andreessen Horowitz, Work-Bench, DFJ Venture, Google Ventures, Data Collective, and TiE Angels
Key Investors in Oration
Chicago Ventures
Chicago Ventures is a private equity firm specializing in growth equity and buyouts, with a focus on identifying strong business opportunities and managerial talent. They typically invest between $2 million and $3 million per transaction and provide active board-level involvement.
Arsenal Venture Partners
Arsenal Growth Equity focuses on providing growth capital to B2B software and tech-enabled services businesses, making minority and control investments in companies at a critical growth stage.
Andreessen Horowitz
Andreessen Horowitz is a prominent venture capital firm known for investing in technology startups across various stages. Their investment thesis often centers on disruptive innovation and market leadership.
What's next for Oration?
The recent major strategic investment signals Oration's transition into a scaling phase, likely focusing on expanding its market reach and enhancing its platform capabilities. With a proven track record of analyzing substantial drug transaction volumes and a clear value proposition for large employers seeking to reduce healthcare expenditures, Oration is well-positioned for further enterprise adoption. Future initiatives may involve deepening partnerships with healthcare providers, expanding the analytics suite, and potentially exploring new market segments within the broader healthcare technology ecosystem. The company's ability to demonstrate tangible cost savings for employers will be a critical driver of its continued growth and success.
See full Oration company page
